These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32681778)

  • 21. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Kuss O; Müssig K; Burkart V; Szendroedi J; Kotzka J; Knebel B; Al-Hasani H; Roden M;
    Diabetologia; 2019 Feb; 62(2):286-291. PubMed ID: 30413829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes.
    Tkáč I; Javorský M; Klimčáková L; Židzik J; Gaľa I; Babjaková E; Schroner Z; Štolfová M; Hermanová H; Habalová V
    Eur J Clin Pharmacol; 2015 Jan; 71(1):59-63. PubMed ID: 25327507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacokinetics of metformin and concentrations of haemoglobin A1C and lactate in Indigenous and non-Indigenous Australians with type 2 diabetes mellitus.
    Duong JK; Kumar SS; Furlong TJ; Kirkpatrick CM; Graham GG; Greenfield JR; Williams KM; Day RO
    Br J Clin Pharmacol; 2015 Apr; 79(4):617-23. PubMed ID: 25291501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-1B rs1143623 and EEF1A1P11-RPL7P9 rs10783050 polymorphisms affect the glucose-lowing efficacy of metformin in Chinese overweight or obese Type 2 diabetes mellitus patients.
    Xiao D; Zhang SM; Li X; Yin JY; Gong WJ; Zheng Y; Xu XJ; Lin X; Ji LN; Liu RR; Tang Q; Zhang W; Zhou HH; Han XY; Liu ZQ
    Pharmacogenomics; 2015; 16(14):1621-9. PubMed ID: 26401715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin decreases glycated albumin to glycated haemoglobin ratio in patients with newly diagnosed type 2 diabetes.
    Sumitani S; Morita S; Deguchi R; Hirai K; Mukai K; Utsu Y; Miki S; Sato B; Nakamura H; Kasayama S; Koga M
    Ann Clin Biochem; 2015 Jan; 52(Pt 1):76-81. PubMed ID: 24604630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2.
    Dong M; Gong ZC; Dai XP; Lei GH; Lu HB; Fan L; Qu J; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):824-9. PubMed ID: 21933224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
    Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
    Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Pettus J; McNabb B; Eckel RH; Skyler JS; Dhalla A; Guan S; Jochelson P; Belardinelli L; Henry RH
    Diabetes Obes Metab; 2016 May; 18(5):463-74. PubMed ID: 26749407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth Differentiation Factor 15 as a Novel Biomarker for Metformin.
    Gerstein HC; Pare G; Hess S; Ford RJ; Sjaarda J; Raman K; McQueen M; Lee S; Haenel H; Steinberg GR;
    Diabetes Care; 2017 Feb; 40(2):280-283. PubMed ID: 27974345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives.
    Martono DP; Heerspink HJL; Hak E; Denig P; Wilffert B
    Diabetes Obes Metab; 2019 Oct; 21(10):2267-2273. PubMed ID: 31168905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT.
    Out M; Becker ML; van Schaik RH; Lehert P; Stehouwer CD; Kooy A
    Pharmacogenomics; 2018 Jun; 19(8):715-726. PubMed ID: 29790415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes.
    Dujic T; Bego T; Malenica M; Velija-Asimi Z; Ahlqvist E; Groop L; Pearson ER; Causevic A; Semiz S
    Bosn J Basic Med Sci; 2019 Nov; 19(4):368-374. PubMed ID: 31070566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
    Au Yeung SL; Schooling CM
    BMJ Open Diabetes Res Care; 2019; 7(1):e000872. PubMed ID: 31908803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.